Key result
Oral tetrahydrobiopterin increased carotid artery compliance (0.61 to 0.73; P<0.0001) and brachial artery FMD in estrogen-deficient postmenopausal women, but had no effect in premenopausal women.
Why the study?
Does tetrahydrobiopterin improve endothelial function and decrease arterial stiffness in estrogen-deficient postmenopausal women?
Population
33 women, comprising estrogen-deficient postmenopausal women and eumenorrheic premenopausal women.
Comparison
Oral administration of tetrahydrobiopterin… vs Baseline measurements, premenopausal women, and…
Design
RCT, Randomization to either 2 days of transdermal estradiol or placebo in the…
Follow-up
3 hours (post-BH4) and 2 days (estradiol/placebo phase)
Authors
Loading...
Tetrahydrobiopterin improves vascular function in estrogen-deficient postmenopausal women; confirms reduced BH4 bioavailability contributes to menopause-related arterial changes.
RCT (n=33)
Randomized
Does tetrahydrobiopterin improve endothelial function and decrease arterial stiffness in estrogen-deficient postmenopausal women?
Absolute Event Rate: 0.73% vs 0.61%
p-value: p=<0.0001
Tetrahydrobiopterin administration improves endothelial-dependent vasodilation and reduces arterial stiffness in estrogen-deficient postmenopausal women, suggesting reduced BH4 bioavailability contributes to age- and menopause-related vascular changes.
Moreau et al. (2012) conducted an RCT in Estrogen-deficient postmenopausal women (n=33). Tetrahydrobiopterin (BH4) and transdermal estradiol vs. Baseline / Placebo was evaluated on Carotid artery compliance (p=<0.0001). Oral tetrahydrobiopterin increased carotid artery compliance (0.61 to 0.73; P<0.0001) and brachial artery FMD in estrogen-deficient postmenopausal women, but had no effect in premenopausal women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: